Patients with three or more cardiac conditions were at highest risk of early death
An increased risk of early death was observed in advanced prostate cancer patients with a history of cardiovascular disease (CVD) starting on abiraterone acetate (Zytiga) or enzalutamide (Xtandi), a retrospective population-based study found.